Predictors of treatment outcome in patients with paediatric onset multiple sclerosis
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Predictors of treatment outcome in patients with paediatric onset multiple sclerosis. / Kopp, Tine Iskov; Blinkenberg, Morten; Chalmer, Thor Ameri; Petersen, Thor; Ravnborg, Mads Henrik; Soelberg Sørensen, Per; Magyari, Melinda.
In: Multiple Sclerosis Journal, Vol. 26, No. 8, 2020, p. 964-975.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Predictors of treatment outcome in patients with paediatric onset multiple sclerosis
AU - Kopp, Tine Iskov
AU - Blinkenberg, Morten
AU - Chalmer, Thor Ameri
AU - Petersen, Thor
AU - Ravnborg, Mads Henrik
AU - Soelberg Sørensen, Per
AU - Magyari, Melinda
PY - 2020
Y1 - 2020
N2 - BACKGROUND: Disease-modifying therapies (DMT) are increasingly used for children with multiple sclerosis (MS) even though most double-blinded randomized controlled trials evaluating efficacy, safety and dosing strategy of a specific drug have included adults.OBJECTIVE: To investigate predictors of treatment outcomes in patients with paediatric onset MS treated with DMTs.METHODS: Prospective cohort study from the nationwide Danish Multiple Sclerosis Registry including all patients with a MS diagnosis who initiated treatment with an approved DMT before the age of 18 (N = 137) and followed until their 25th birthday. Selected baseline predictors were tested in univariate and multivariate regression models.RESULTS: Multivariate analyses showed that being female and having disease duration for 2 or more years prior to DMT initiation predicted a higher relapse rate. In addition, disease duration and baseline expanded disability status scale (EDSS) predicted both confirmed disability worsening and improvement. We found no difference in treatment outcome between children with MS onset before and after the age of 13 years.CONCLUSIONS: The efficacy of DMT in paediatric onset MS patients is comparable to that seen in adult onset MS patients. Earlier treatment start is associated with a beneficial prognosis in the paediatric cohort.
AB - BACKGROUND: Disease-modifying therapies (DMT) are increasingly used for children with multiple sclerosis (MS) even though most double-blinded randomized controlled trials evaluating efficacy, safety and dosing strategy of a specific drug have included adults.OBJECTIVE: To investigate predictors of treatment outcomes in patients with paediatric onset MS treated with DMTs.METHODS: Prospective cohort study from the nationwide Danish Multiple Sclerosis Registry including all patients with a MS diagnosis who initiated treatment with an approved DMT before the age of 18 (N = 137) and followed until their 25th birthday. Selected baseline predictors were tested in univariate and multivariate regression models.RESULTS: Multivariate analyses showed that being female and having disease duration for 2 or more years prior to DMT initiation predicted a higher relapse rate. In addition, disease duration and baseline expanded disability status scale (EDSS) predicted both confirmed disability worsening and improvement. We found no difference in treatment outcome between children with MS onset before and after the age of 13 years.CONCLUSIONS: The efficacy of DMT in paediatric onset MS patients is comparable to that seen in adult onset MS patients. Earlier treatment start is associated with a beneficial prognosis in the paediatric cohort.
U2 - 10.1177/1352458519846100
DO - 10.1177/1352458519846100
M3 - Journal article
C2 - 31081451
VL - 26
SP - 964
EP - 975
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
SN - 1352-4585
IS - 8
ER -
ID: 261236946